Rafael Holdings Inc.

11/11/2021 | Press release | Distributed by Public on 11/11/2021 11:06

Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma